TCRX Stock Overview
A clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
TScan Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.85 |
| 52 Week High | US$9.69 |
| 52 Week Low | US$1.84 |
| Beta | 0.91 |
| 1 Month Change | -28.21% |
| 3 Month Change | -58.91% |
| 1 Year Change | -74.09% |
| 3 Year Change | -51.06% |
| 5 Year Change | n/a |
| Change since IPO | -82.43% |
Recent News & Updates
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
Feb 10Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?
Nov 06
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology
Aug 26Recent updates
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
Feb 10Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?
Nov 06TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology
Aug 26Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price
Mar 23Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target
Mar 11TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M
Aug 10TScan Therapeutics appoints Debora Barton as Chief Medical Officer
Jul 07Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
May 22Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Jan 17We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate
Oct 18Shareholder Returns
| TCRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.4% | -3.2% | -2.5% |
| 1Y | -74.1% | -9.1% | 13.1% |
Return vs Industry: TCRX underperformed the US Biotechs industry which returned -6.9% over the past year.
Return vs Market: TCRX underperformed the US Market which returned 15.3% over the past year.
Price Volatility
| TCRX volatility | |
|---|---|
| TCRX Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TCRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TCRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 194 | Gavin MacBeath | www.tscan.com |
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors.
TScan Therapeutics, Inc. Fundamentals Summary
| TCRX fundamental statistics | |
|---|---|
| Market cap | US$118.66m |
| Earnings (TTM) | -US$111.30m |
| Revenue (TTM) | US$9.36m |
11.1x
P/S Ratio-0.9x
P/E RatioIs TCRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCRX income statement (TTM) | |
|---|---|
| Revenue | US$9.36m |
| Cost of Revenue | US$100.40m |
| Gross Profit | -US$91.04m |
| Other Expenses | US$20.26m |
| Earnings | -US$111.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.97 |
| Gross Margin | -972.44% |
| Net Profit Margin | -1,188.88% |
| Debt/Equity Ratio | 13.4% |
How did TCRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/03 04:44 |
| End of Day Share Price | 2025/03/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TScan Therapeutics, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Justin Zelin | BTIG |
| Andrew Fein | H.C. Wainwright & Co. |